MRSA Is More Prevalent In Paediatric Healthcare Than Previously Thought - Birmingham Children's Hospital, UK

MRSA Is More Prevalent In Paediatric Healthcare Than Previously Thought - Birmingham Children's Hospital, UK
Birmingham Children's Hospital has introduced a new way of detecting the MRSA superbug amongst its most critically ill young patients. The test, developed by molecular diagnostics company Cepheid, has so far proven to be 100% accurate and is allowing doctors at the hospital to identify if a patient to be admitted to the ICU has MRSA within an hour.

Acute Cardiac Care 2008
Chest pain - or at worst a cardiac arrest - is invariably the prelude to one of the most critical episodes of health care. Acute cardiac care, that first emergency phase in which the chest pain is assessed and its cause treated, embraces a broad spectrum of diagnoses ranging from unstable angina to acute heart failure, from myocardial infarction (with or without ST elevation) to other life-threatening disorders of the heart.

Eating Whole Grains Lowers Heart Failure Risk, According To New Study
About 5 million people in the United States suffer from heart failure (HF). While some reports indicate that changes to diet can reduce HF risk, few large, prospective studies have been conducted. In a new study researchers observed over 14,000 participants for more than 13 years and found that whole grain consumption lowered HF risk, while egg and high-fat dairy consumption raised risk. Other food groups did not directly affect HF risk.

The Future Of Anti-Microbials Is Here
The emergence of antibiotic-resistant "superbugs" underscores the need for new drugs and therapies for protecting the public from pathogenic organisms. Since bacteria rapidly evolve to evade the action of new antibiotics, the drugs quickly lose their effectiveness. The prevalence of MRSA (methicillin-resistant Staphylococcus aureus) illustrates the severity of the problem.

New Treatment Targets Result From First Comprehensive Genomic Study Of The Common Cold
Scientists from Procter & Gamble (P&G), the University of Calgary and the University of Virginia have announced results from the first study to examine the entire human genome's response to the most common cold virus, human rhinovirus. The research confirmed, at the genomic level, that the immune system response to the virus, and not the virus by itself, results in common cold symptoms.

Angular Cheilitis Treatment - Cure Angular Cheilitis Today!

In order for an Angular Cheilitis treatment to work efficiently, directly and absolutely, it also should be simple, and have one focus of attack aimed at the root of the problem. For this to come about, we need to examine the main cause of Angular Cheilitis, and then we can formulate a proper treatment. To get right down to it, the primary active agent involved is fungal bacteria. It is this which infects the corners of the mouth, creating the lesions resembling infected paper cuts.

Inoperable Or Metastatic Tumors - Calando Pharmaceuticals Announces Completion Of IT-101 Phase 1 Clinical Study

Inoperable Or Metastatic Tumors - Calando Pharmaceuticals Announces Completion Of IT-101 Phase 1 Clinical Study
Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today completion of the IT-101 Phase I clinical study conducted at City of Hope in Duarte, California. The company expects the entire study data to be published in early 2009. IT-101 is an experimental, nanoparticle therapeutic that consists of the drug camptothecin (CPT) conjugated to a cyclodextrin polymer.

Cancer Drug Vidaza(R) Receives Positive Opinion From European Regulatory Authority For Treatment Of MDS And AML
The positive opinion includes important survival data from the AZA-001 trial in higher-risk MDS patients. The CHMP, which reviews applications for all 27 Member States in the European Union (EU) as well as Norway and Iceland, has recommended approval for azacitidine. The CHMP's positive opinion will be forwarded to the European Commission, which generally follows the recommendation of the CHMP and typically issues final marketing approval within two to three months.